Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (375 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Feb 2022 – 20 Aug 2026, limited by HDFC NIFTY 100 Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC NIFTY 100 Index Fund | Nifty 100 |
|---|---|---|
| 23 Feb 2022 | ₹100.00 | ₹100.00 |
| 10 Jul 2022 | ₹95.53 | ₹95.08 |
| 23 Nov 2022 | ₹107.37 | ₹106.72 |
| 09 Apr 2023 | ₹101.39 | ₹100.82 |
| 23 Aug 2023 | ₹113.41 | ₹112.09 |
| 07 Jan 2024 | ₹128.75 | ₹127.22 |
| 23 May 2024 | ₹140.83 | ₹138.84 |
| 06 Oct 2024 | ₹153.44 | ₹150.84 |
| 20 Feb 2025 | ₹138.18 | ₹135.53 |
| 06 Jul 2025 | ₹154.40 | ₹150.91 |
| 20 Nov 2025 | ₹159.02 | ₹154.89 |
| 05 Apr 2026 | ₹138.56 | ₹134.91 |
| 20 Aug 2026 | ₹151.88 | ₹147.00 |
| Metric | HDFC · Direct NAV ₹15.17 Very High risk ★★★☆☆ | Category median Index Funds · 375 funds |
|---|---|---|
| -0.45% | +5.66% | |
| +10.50% | +8.82% | |
| — | +9.15% | |
| — | +11.72% | |
| +9.76% | +7.67% | |
| +8.31% | — | |
| +13.36% | +12.67% | |
| — | +13.64% | |
| — | +12.84% | |
| Risk | ||
| 13.67% | 13.97% | |
| 0.29 | 0.24 | |
| 0.40 | 0.36 | |
| -17.34% | -16.12% | |
| Nifty 100 | — | |
| +0.71% | +0.84% | |
| 1.00 | 1.00 | |
| 101.8% | 102.2% | |
| 98.0% | 97.2% | |
| 0.36% | 0.36% | |
| ₹426.88Cr | ₹177.09Cr | |
| None | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 9% | 35% | |
| Arun Agarwal | — | |
| 23 Feb 2022 | — | |
| 100 | — | |
| 43.6% | — | |
| 0.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.